Prelude Highlights Continued Strength of Discovery Engine :

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...

Related Keywords

United States , American , Andrew Combs , Peggy Scherle , Helen Shik , Lindsey Trickett , Shik Communications , Prelude Therapeutics Incorporated Nasdaq , American Association For Cancer Research , Linkedin , Exchange Commission , Therapeutics Incorporated , American Association , Cancer Research , Annual Meeting , Chief Chemistry Officer , Chief Scientific Officer , Preclinical Characterization , Highly Potent , Orally Bioavailable Targeted Protein Degrader , Novel Highly Selective Cyclin Dependent Kinase , Has Potent Antitumor Activity , Various Lymphoid , Brain Penetrant , Highly Effective , Preclinical Models , Breast Cancer , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Nasdaq Prld , Prelude Therapeutics , Nc , Aacr 2024 , Marca2 , Marca2 Protein Degrader , Precision Oncology , Reclinical , Phase 1 Study ,